Pfizer closes Baxter vaccine acquisition; Bavarian Nordic Ebola booster tests begin in the U.K.;

> Pfizer ($PFE) has closed its deal for Baxter's ($BAX) marketed vaccines portfolio. Release

> The first clinical trials of a Bavarian Nordic's Ebola vaccine booster, which may improve the effects of a vaccine from GlaxoSmithKline ($GSK), have begun at the U.K.'s Oxford University. Report

> The U.S. has approved GlaxoSmithKline's purchase of the bulk of Novartis' ($NVS) vaccine business. Report

> This year's flu vaccine is not as effective against the current strain of the influenza virus because the virus has mutated, the CDC says. Report

> Novavax ($NVAX) has won FDA fast-track designation for its RSV F vaccine. Release

And Finally... UC Berkeley students are working on a portable chip that healthcare providers can access without the Internet to view patient vaccination records, a tool that could make it easier to provide vaccines to children in developing countries. More